E-DRUG: EU Regulation text on compulsory licensing of patents
---------------------------------------------------
Here below the link of the Regulation of the European Parliament and the
Council on compulsory licensing of patents relating to the manufacture of
pharmacutical products for export countries with public health adopted by
the EU on April 27th, 2006.
http://register.consilium.eu.int/pdf/en/05/st03/st03674.en05.pdf
[Link may need repair!]
The text will be published after the 17 of May, and it will enter into
force on the twentieth day following that of its publication in the
Official Journal of the European Union.
Alexandra Heumber
Médecins Sans Frontières
Access to Medicines Campaign
EU Advocacy Liaison Officer
C/O MSF-B
Rue Dupré, 94
1090 Brussels
++32 (0) 2 474 75 09 (Dir off)
++ 32 (0) 479 514 900 (Mob)
++ 32 (0) 2 474 75 75 (Fax)
Alexandra.HEUMBER@brussels.msf.org
Press release:
The Council adopted[1] today in first reading a Regulation on compulsory licensing of patents relating to the manufacture of pharmaceutical products for export to countries with public health problems. (PE-CONS 3674/05)
This Regulation aims at facilitating and regulating at Community level the granting of compulsory licences for the supply of patented pharmaceutical products to countries in need. After its entry into force, it will allow to handle cases of public health emergencies, such as the avian flu, in poor developing countries lacking the capacity to manufacture such medicines locally.
Intensive cooperation between the Council and the European Parliament has allowed the rapid adoption of this Regulation which is directly applicable in all Member States since the date of its entry into force i.e. on the twentieth day following its publication in the Official Journal of the EU.
The two co legislators agreed to modify the Commission's proposal in particular by widening the list of countries eligible to benefit from the import of products licensed under the Regulation to include not only members of the WTO but also other least-developed and developing countries.
The text of the Regulation makes clear that the compulsory licensing system set up by this Regulation is intended to address public health problems and therefore it should not be used by countries to pursue industrial or commercial policy objectives. Moreover it specifies that products manufactured pursuant to this Regulation reach only those who need them and are not diverted from those for whom they were intended.
The issuing of compulsory licences under this Regulation imposes clear conditions upon the licensee as regards the acts covered by the licence, the identification of the pharmaceutical products manufactured under the licence and the countries to which the products will be exported.
----------------------------------------------------------------
[1] The German delegation abstained.
[Anybody who knows why Germany abstained? KM, moderator]